Mode
Text Size
Log in / Sign up
N/A Completed N=415

Prospective Evaluation of Open Irrigated Ablation Catheters With High Resolution Mapping to Treat Paroxysmal Atrial Fibrillation

Source: ClinicalTrials.gov NCT03729830 ↗
Enrolled (actual)
415
Serious AEs
35.3%
Results posted
Jan 2026
Primary outcomePrimary: Number of Participants Safety Event-free at 12 Months Post Procedure — 368 Number of Participants

Summary

To obtain data for the Rhythmia™ Mapping System in conjunction with Boston Scientific Open-Irrigated (OI) Catheters for ablation of Paroxysmal Atrial Fibrillation (PAF) according to current international and local guidelines. Primary objective: To assess acute and long-term outcomes for the Rhythmia Mapping System in conjunction with Boston Scientific Open-Irrigated Ablation Catheters to treat de novo Paroxysmal Atrial Fibrillation. De Novo PAF is defined as subjects undergoing first ablation procedure for PAF with no prior left atrial ablation (RF, Cryo, Surgical).

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants Safety Event-free at 12 Months Post Procedure
368
PRIMARY
Number of Participants Effectiveness Event -Free at 12 Months Post Procedure
218
SECONDARY
Number of Participants Event Free Rate (Secondary)
102

Eligibility Criteria

Inclusion Criteria

  • History of recurrent symptomatic Paroxysmal Atrial Fibrillation, defined as AFib that terminates spontaneously or with intervention within seven days of onset. Minimum documentation includes a physician's note indicating recurrent self-terminating Atrial Fibrillation AND one electrocardiographically documented AF episode within 6 months prior to enrollment.
  • Subjects who are eligible for an ablation procedure for Paroxysmal Atrial Fibrillation with the Rhythmia Mapping system according to current international and local guidelines
  • Subjects who are eligible for an ablation procedure for Paroxysmal Atrial Fibrillation with a Boston Scientific Open-Irrigated Ablation Catheter according to current international and local guidelines
  • Subjects who are willing and capable of providing informed consent
  • Subjects who are willing and capable of participating in all testing associated with this clinical investigation at an approved clinical investigational center
  • Subjects whose age is 20 years or above, or who are of legal age to give informed consent specific to state and national law.

Exclusion Criteria

  • Subjects enrolled in any other concurrent clinical study, with the exception of local mandatory governmental registries and observational studies/registries, without the written approval from Boston Scientific
  • Subjects unable or unwilling to complete follow-up visits and examination for the duration of the study
  • Subjects who have undergone any previous left atrial cardiac ablation (RF, Cryo, surgical)
  • Subjects who have undergone any cardiac ablation within 30 days prior to enrollment
  • Unrecovered/unresolved Adverse Events from any previous invasive procedure
  • Life expectancy <= three years per physician opinion
  • Women of childbearing potential who are, or plan to become, pregnant during the time of the study (method of assessment upon physician's discretion)
  • Known cardiac thrombus within 60 days prior to enrollment
  • History of CVA, TIA or PE within 90 days prior to enrollment
  • Implanted pacemaker, ICD, or CRT leads within 90 days prior to enrollment
  • Implanted Left atrial appendage closure device prior to the index procedure
  • Prosthetic mitral or tricuspid heart valves (subjects with successful mitral valve repair allowed- annular ring constitutes repair)
  • Left atrial diameter greater than 5.5cm
  • Documented or suspected stenosis of any pulmonary veins.
  • Atrial fibrillation secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause.
  • Contraindication for anticoagulation
  • Clinically significant mitral valve regurgitation or stenosis per investigator discretion.
  • Any cardiac surgery ≤ 90 days from consent date.
  • Any electrocardiographically documented episode of Persistent AFib, defined as AFib lasting longer than 7 days from onset.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03729830). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search